Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions.

Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK.

J Hum Genet. 2008;53(8):709-17. doi: 10.1007/s10038-008-0302-2. Epub 2008 Jun 10.

PMID:
18542840
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents.

Shen J, Ordovas JM.

Clin Chem. 2009 Feb;55(2):256-64. doi: 10.1373/clinchem.2008.117754. Epub 2008 Dec 12. Review.

PMID:
19074515
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
[PubMed - indexed for MEDLINE]
4.

Combination of fenofibrate with non-statin drug regimens.

Agouridis AP, Filippatos TD, Derdemezis CS, Mikhailidis DP, Elisaf MS.

Curr Pharm Des. 2010 Oct;16(30):3401-16. Review.

PMID:
20819059
[PubMed - indexed for MEDLINE]
5.

Fenofibrate and metabolic syndrome.

Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK.

Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):138-48. Review.

PMID:
20406163
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk